Capacity Development - Nanopore MinION

NIH RePORTER · FDA · U19 · $127,358 · view on reporter.nih.gov ↗

Abstract

While the Illumina platform is the most widely used technology in whole genome sequencing (WGS), an emerging technology shows exciting promise. Because the Oxford Nanopore technology produces very long reads, it is possible to ‘close’ genomes, identifying chromosomes from plasmids. Combining bioinformatics tools to close the genome with tools to identify alleles contributing to AR conditions, it will be possible to develop a bioinformatics pipeline to determine the location of the alleles within a genome. WA PHL plans to develop these tools along with a laboratory protocol for routine use of the MinION in AR analyses, and validate these paths for clinical reporting. WAPHL holds several key elements making this project feasible, including two microbiologists already trained in the technology, a resident bioinformaticist, an AWS account as an environment to develop analysis tools, and several microbiologists already trained in the concepts of WGS.

Key facts

NIH application ID
10173519
Project number
1U19FD007085-01
Recipient
WASHINGTON STATE DEPARTMENT OF HEALTH
Principal Investigator
Philip Dykema
Activity code
U19
Funding institute
FDA
Fiscal year
2020
Award amount
$127,358
Award type
1
Project period
2020-09-01 → 2021-06-30